文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

分次立体定向放疗治疗完整脑转移瘤

Fractionated stereotactic radiation therapy for intact brain metastases.
PubMed 文献 · Adv Radiat Oncol · 2017-07-19

本研究评估分次立体定向放疗(FSRT)对182个未经治疗完整脑转移瘤的安全性和疗效,72例患者接受25或30 Gy/5次。12个月局部控制率为86%,肿瘤<3 cm和30 Gy处方的局部控制率更高;4例(6%)出现需手术的4级中枢神经系统毒性。

要点

  • FSRT对完整脑转移瘤12个月局部控制率达86%。
  • 肿瘤<3 cm和30 Gy处方的12个月局部控制率分别更高。
  • 4级中枢神经系统毒性发生率为6%,无不可逆3级或5级毒性。

核心结论

  • FSRT治疗脑转移瘤局部控制率高且严重毒性风险低。
  • 局部控制与较小肿瘤直径和较高处方剂量相关。
  • FSRT是不适合单次放疗者的可行选择。

研究设计与样本

  • 单中心研究,72例患者共182个未经治疗的完整脑转移瘤接受基于直线加速器的FSRT。
  • 靶区接受25或30 Gy分5次照射,同一疗程所有靶区不论大小接受相同处方。
  • 毒性按放射治疗肿瘤学组中枢神经系统毒性标准记录。

主要发现

  • 中位随访5个月(范围1-71个月),12个月局部控制率的Kaplan-Meier估计为86%。
  • 肿瘤直径<3 cm的12个月局部控制率为95%,≥3 cm为61%(P < .001)。
  • 30 Gy处方的12个月局部控制率为91%,25 Gy为75%(P = .015)。
  • 多因素分析显示肿瘤直径≥3 cm增加局部失败(HR 8.11,范围2.09-31.50,P = .003),30 Gy处方减少局部失败(HR 0.26,范围0.07-0.93,P = .038)。
  • 4级中枢神经系统毒性发生于4例(6%)需手术,无患者出现不可逆3级或5级毒性;肿瘤直径增加与毒性风险增加相关(HR 2.45,范围1.04-5.742,P = .04)。

关键数值与推荐

  • 靶区处方剂量为25或30 Gy分5次。
  • 12个月局部控制率总体86%,<3 cm为95%,≥3 cm为61%(P < .001)。
  • 12个月局部控制率30 Gy为91%,25 Gy为75%(P = .015)。
  • 4级中枢神经系统毒性发生率6%(4例)。

临床怎么用

  • 对于不适合单次放疗的脑转移瘤患者,可考虑FSRT。
  • 较小肿瘤(<3 cm)和较高处方剂量(30 Gy/5次)与更好局部控制相关。
  • 肿瘤直径≥3 cm时局部失败和毒性风险增加,需个体化权衡。

局限性

  • 中位随访仅5个月,长期疗效和毒性数据有限。
  • 回顾性设计可能引入选择偏倚。
  • 样本量较小(72例患者),统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Limited data exist on fractionated stereotactic radiation therapy (FSRT) for brain metastases. We sought to evaluate the safety and efficacy of FSRT and further define its role in brain metastasis management. METHODS AND MATERIALS: A total of 72 patients were treated with linear accelerator-based FSRT to 182 previously untreated, intact brain metastases. Targets received 25 or 30 Gy in 5 fractions. All targets within the same course received the same prescription regardless of size. Toxicity was recorded per Radiation Therapy Oncology Group central nervous system toxicity criteria. RESULTS: The median follow-up was 5 months (range, 1-71 months). The Kaplan-Meier estimate of 12-month local control was 86%. Tumors <3 cm in diameter demonstrated improved 12-month local control of 95% compared with 61% in tumors ≥3 cm (P < .001). The Kaplan-Meier estimate of 12-month local control was 91% in tumors treated with 30 Gy and only 75% in tumors treated with 25 Gy (P = .015). Tumor diameter ≥3 cm resulted in increased local failure, and a 30 Gy prescription resulted in decreased local failure on multivariate analysis (hazard ratio [HR], 8.11 [range, 2.09-31.50; P = .003] and HR, 0.26 [range, 0.07-0.93; P = .038]). Grade 4 central nervous system toxicity occurred in 4 patients (6%) requiring surgery, and no patient experienced irreversible grade 3 or 5 toxicity. Increasing tumor diameter was associated with increased toxicity risk (HR, 2.45 [range, 1.04-5.742; P = .04]). CONCLUSIONS: FSRT for brain metastases appears to demonstrate a high rate of local control with minimal risk of severe toxicity. Local control appears to be associated with smaller tumor sizeand a higher prescription dose. FSRT is a viable option for those who are poor single-fraction candidates.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Marcrom SR, McDonald AM, Thompson JW, et al. Fractionated stereotactic radiation therapy for intact brain metastases. Adv Radiat Oncol. 2017. PMID: 29204523. doi:10.1016/j.adro.2017.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。